Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Clinical Characteristics and Outcome of 41 Patients with Upper GI Diffuse B-Cell Non-Hodgkin Lymphoma. Results of Brazilian-Italy Lymphoma Registry

Marcia T Delamain, MD, Eliana C M Miranda, MD PhD, Merli Francesco, MD, Carlos S Chiattone, MD PhD, Anna Fedina, Stefano Luminari, MD, Carmino Antonio De Souza, MD PhD, Federico Massimo, MD

Blood (2014) 124 (21): 5400.

https://doi.org/10.1182/blood.V124.21.5400.5400

Published: 2014

Journal Articles

Lack Of Advantage Of Peripheral Blood Hematopoietic Stem Cell Transplantation Over Bone Marrow From HLA Matched Related Donors After Myeloablative Conditioning For Hematologic Malignancies

Paulo Vidal Campregher, MD, Nelson Hamerschlak, MD, PhD, Vergilio Antonio Renzi Colturato, MD, Marcos Mauad, MD, Mair Pedro de Souza, MD, Luis Fernando S Bouzas, MD, PhD, Rita deCássia Barbosa Tavares, MD, Jose C. Barros, MD, Ricardo Chiattone, MD, Lisandra della Costa, MD, Lucia Silla, MD, PhD, Afonso Celso Vigorito, MD, PhD, Eliana C M Miranda, MEd, Vaneuza Araujo Moreira, MD, Mary E.D. Flowers, MD

Blood (2013) 122 (21): 5470.

https://doi.org/10.1182/blood.V122.21.5470.5470

Published: 2013

Journal Articles

Predictive Value Of Early Molecular Responses In Outcomes Of Patients With Chronic Myeloid Leukemia Treated With Imatinib In First-Line Therapy

Katia B. Pagnano, MD, PhD, Bruna Vergilio, Eliana C M Miranda, MEd, Marcia Torresan Delamain, MD, Maria Helena De Almeida, RN, Vagner O Duarte, Gislaine O. Duarte, PhD, Carmino A De Souza, Sr., MD, PhD, Irene Lorand-Metze, MD, PhD

Blood (2013) 122 (21): 4941.

https://doi.org/10.1182/blood.V122.21.4941.4941

Published: 2013

Journal Articles

Evaluation Of hOCT1expression In Patients With Chronic Myeloid Leukemia (CML) Treated With Imatinib In First Line

Cintia Do Couto Mascarenhas, PhD, Maria Helena Almeida, PhD, Eliana C M Miranda, MEd, Bruna Virgilio, Marcia Torresan Delamain, MD, Gislaine O. Duarte, PhD, Vagner O Duarte, Carmino A De Souza, Sr., MD, PhD, Katia B. Pagnano, MD, PhD

Blood (2013) 122 (21): 4041.

https://doi.org/10.1182/blood.V122.21.4041.4041

Published: 2013

Journal Articles

Early Molecular Response Is Predictive Of Overall, Progression-Free and Event-Free Survival In Chronic Myeloid Leukemia Using Second-Generation Tyrosine Kinase Inhibitors After Imatinib Treatment

Beatriz F Ribeiro, Bruna Vergilio, Eliana C M Miranda, MEd, Maria Helena Almeida, RN, Marcia Torresan Delamain, MD, Rosana A Silveira, MSc, Carmino A De Souza, Sr., MD, PhD, Dulcinéia Martins Albuquerque, BSc, MSc, PhD, Andrey dos Santos, PhD, Irene Lorand-Metze, MD, PhD, Vagner O Duarte, Gislaine O. Duarte, PhD, Katia B. Pagnano, MD, PhD

Blood (2013) 122 (21): 1326.

https://doi.org/10.1182/blood.V122.21.1326.1326

Published: 2013

Journal Articles

Metabolomic Model For Chronic Gvhd Diagnosis

Marcos Rodrigo Alborghetti, Sr., PhD, Maria Elvira P Corrêa, DDS, PhD, Andreia Aparecida da Silva, DDS, PhD, Eliana C M Miranda, MEd, Carmino A De Souza, Sr., MD, PhD, Mauricio L Sforça, Sr., PhD, Ana Carolina de Mattos Zeri, PhD

Blood (2013) 122 (21): 3304.

https://doi.org/10.1182/blood.V122.21.3304.3304

Published: 2013

Journal Articles

Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors

Beatriz F Ribeiro, Eliana C M Miranda, MEd, Marcia T Delamain, MD, Gislaine Borba Oliveira, MD,, Maria Helena Almeida, RN, Vagner O Duarte, Irene L Metze, MD, PhD, Carmino A De Souza, Sr., MD, PhD, Rosana A Silveira, Katia B. Pagnano, MD, PhD

Blood (2013) 122 (21): 5189.

https://doi.org/10.1182/blood.V122.21.5189.5189

Published: 2013

Journal Articles

Early Assessment of Molecular Response in Chronic Myeloid Leukemia Patients On Dasatinib After Imatinib Failure Identify Patients with Poor Cytogenetic and Molecular Responses

Katia B. Pagnano, MD, Beatriz F Ribeiro, Eliana C M Miranda, Marcia T Delamain, MD, Carmino Antonio De Souza, PhD, Gislaine O Duarte, MD, Bruna Vergilio, Dulcinéia Martins Albuquerque, BSc, MSc, PhD, Andrey dos Santos, PhD, Anderson Tavares, Irene Lorand-Metze, MD, PhD

Blood (2012) 120 (21): 3787.

https://doi.org/10.1182/blood.V120.21.3787.3787

Published: 2012

Journal Articles

EUTOS Score Is Predictive of Event-Free Survival, but Not for Progression-Free and Overall Survival in Patients with Early Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib: A Single Institution Experience

Katia B. Pagnano, MD, Irene Lorand-Metze, MD, PhD, Eliana C M Miranda, Vagner O Duarte, Marcia T Delamain, MD, Gislaine O Duarte, MD, Carmino Antonio De Souza, MD, PhD

Blood (2012) 120 (21): 1681.

https://doi.org/10.1182/blood.V120.21.1681.1681

Published: 2012

Journal Articles

Hematopoietic Cell Transplantation Co-Morbidity Index (HCT-CI) to Predict Non Relapse Mortality After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Marcos Paulo Colella, MD, Eliana C M Miranda, Francisco J. P Aranha, Md, Virginio C.A Fernandes-Junior, Md, Samuel de Souza Medina, MD, Carmino De Souza, MD, PhD, Afonso Celso Vigorito, MD, PhD

Blood (2011) 118 (21): 4561.

https://doi.org/10.1182/blood.V118.21.4561.4561

Published: 2011

Journal Articles

A Phase III Study Comparing Thalidomide/Cyclophosphamide/ Dexa Vs Thalidomide/Dexa Vs Thalidomide/Melphalan/Prednisone In De Novo Multiple Myeloma Patients Not Eligible for ASCT

Edvan Crusoe, MD, Angelo Maiolino, MD, PhD, Rosane Bittencourt, MD, Dorotea Beatriz Fantl, MD, James Maciel, MD, Manuella Sampaio, MD, PhD, Adriana Quero, MD, Ana Lucia Peres, MD, Eliana C M Miranda, Daniel Mercante, MD, Flavia Parra, BSc, PhD, Carlos S Chiattone, MD, PhD, Vania Hungria, MD, PhD

Blood (2011) 118 (21): 5117.

https://doi.org/10.1182/blood.V118.21.5117.5117

Published: 2011

Journal Articles

Evaluation of Angiogenesis and the CD57+ Lymphocytic Population on Bone Marrow Biopsies (BM) in Multiple Myeloma Patients Treated with Thalidomide (Thal)

Edvan Crusoe, MD, Adriana Quero, MD, Eliana C M Miranda, Manuella Sampaio, MD, PhD, Ana Lucia Peres, MD, Flavia Parra, BSc, PhD, Igor Campos, MD, Carlos S Chiattone, MD, PhD, Roberto Pinto Paes, MD, PhD, Vania Hungria, MD, PhD

Blood (2011) 118 (21): 5095.

https://doi.org/10.1182/blood.V118.21.5095.5095

Published: 2011

Journal Articles

Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitors– A Study on Behalf of Latin American Leukemia Net (Lalnet)

Blood (2011) 118 (21): 1701.

https://doi.org/10.1182/blood.V118.21.1701.1701

Published: 2011

Journal Articles

High Adherence to Tyrosine Kinase Inhibitors Seems to Be Related to Best Cytogenetic Responso In the Hasford Lower Risk Graup In Chronic Myeloid Leukemia.

Maria Helena Almeida, RN, Katia B. Pagnano, MD, Helia Souza, Eliana C M Miranda, Carmino De Souza, MD, PhD

Blood (2010) 116 (21): 4477.

https://doi.org/10.1182/blood.V116.21.4477.4477

Published: 2010

NARROW

Clinical Characteristics and Outcome of 41 Patients with Upper GI Diffuse B-Cell Non-Hodgkin Lymphoma. Results of Brazilian-Italy Lymphoma Registry

Lack Of Advantage Of Peripheral Blood Hematopoietic Stem Cell Transplantation Over Bone Marrow From HLA Matched Related Donors After Myeloablative Conditioning For Hematologic Malignancies

Predictive Value Of Early Molecular Responses In Outcomes Of Patients With Chronic Myeloid Leukemia Treated With Imatinib In First-Line Therapy

Evaluation Of hOCT1expression In Patients With Chronic Myeloid Leukemia (CML) Treated With Imatinib In First Line

Early Molecular Response Is Predictive Of Overall, Progression-Free and Event-Free Survival In Chronic Myeloid Leukemia Using Second-Generation Tyrosine Kinase Inhibitors After Imatinib Treatment

Metabolomic Model For Chronic Gvhd Diagnosis

Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors

Early Assessment of Molecular Response in Chronic Myeloid Leukemia Patients On Dasatinib After Imatinib Failure Identify Patients with Poor Cytogenetic and Molecular Responses

EUTOS Score Is Predictive of Event-Free Survival, but Not for Progression-Free and Overall Survival in Patients with Early Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib: A Single Institution Experience

Hematopoietic Cell Transplantation Co-Morbidity Index (HCT-CI) to Predict Non Relapse Mortality After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

A Phase III Study Comparing Thalidomide/Cyclophosphamide/ Dexa Vs Thalidomide/Dexa Vs Thalidomide/Melphalan/Prednisone In De Novo Multiple Myeloma Patients Not Eligible for ASCT

Evaluation of Angiogenesis and the CD57+ Lymphocytic Population on Bone Marrow Biopsies (BM) in Multiple Myeloma Patients Treated with Thalidomide (Thal)

Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitors– A Study on Behalf of Latin American Leukemia Net (Lalnet)

High Adherence to Tyrosine Kinase Inhibitors Seems to Be Related to Best Cytogenetic Responso In the Hasford Lower Risk Graup In Chronic Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only